



**Expert Group Meeting on Strengthening Regional Cooperation in
Healthcare Biotechnology and Biomedical Sector
ESCAP-APCTT**

Assoc Prof Dr Ghows Azzam

Director

Malaysia Genome and Vaccine Institute

22 MAC 2022

CAPACITY BUILDING FOR THE PRODUCTION OF LOCAL HUMAN VACCINE – LESSONS FROM COVID-19 PANDEMIC

01

National Vaccine Development Roadmap

- National Science Council Bil.2/2020, 14 July 2020
 - Commissioned a study for the National Vaccine Development Roadmap



02

National Vaccine Institute

- The Prime Minister in a statement gave the mandate to MOSTI to focus on the development of a local human vaccine

PM: MOH handles vaccinations, health strategies; Mosti to focus on R&D



Bernama

Published: Aug 28, 2021 4:16 PM · Updated: 6:16 PM

All vaccination-related programmes and health strategies related to Covid-19 will from now on only be handled by the Health Ministry through its newly appointed minister Khairy Jamaluddin, said Prime Minister Ismail Sabri Yaakob.


He said the Science, Technology and Innovation Ministry (Mosti), now helmed by former health minister Dr Adham Baba, will focus on research and development (R&D) to produce Covid-19 vaccines.

Launching of the National Vaccine Development Roadmap (NVDR) and transformation of Malaysia Genome and Vaccine Institute (MGVI) on 1st November 2021

“Through the implementation of PPVN and establishment of MGVI, highly skilled human capital in various fields of research especially those related to healthcare and vaccines can be produced.”

Datuk Seri Ismail Sabri Yaakob

Prime Minister



NATIONAL VACCINE DEVELOPMENT ROADMAP BACKGROUND & OBJECTIVES

National Science Council Meeting in 2020

Proposal to develop a roadmap on vaccine development

MOSTI and MOH co-chair the committee to monitor development of roadmap

Development of the National Vaccine Development Roadmap



ASPIRATION

Malaysia to become self-sufficient in vaccine manufacturing and R&D within 10 years


ROADMAP OBJECTIVES

To develop a national roadmap that will enable stakeholders and government to understand the as-is scenario and the gaps within the vaccine industry

To formulate a strategic plan from a short term, mid-term and long term perspective to develop Malaysia's capability towards becoming a vaccine producing country

PROPOSED STRATEGY FRAMEWORK

Proposed strategy framework will focus on each Critical Pathways to formulate specific strategies that will enable local vaccine development



- Develop a robust governance structure, with MOSTI as lead and MOH as the regulator and adoption of PPP model for implementing & monitoring the program



- Expand fill & finish, while developing capabilities for bulk manufacturing and end-to-end vaccine production and position Malaysia as the halal vaccine hub



- Position Malaysia as a hub for clinical trials by enhancing its capabilities in pre-clinical and first in-human studies



- Acquire & train sufficient talent pool to have adequate skills related to vaccine development to support the local vaccine ecosystem



- Targetted R&D on vaccines for local consumption and also look at export to ensure the balance between self-sufficiency and driving the economy through technology acquisition, with halal vaccine as a niche



- Continuous efforts to communicate and publicize Malaysia's efforts in vaccine development , as well as interaction with governments and industry players through vaccine diplomacy



MGVI
Malaysia Genome
and Vaccine Institute

Research and Development

ICR
MINISTRY OF HEALTH MALAYSIA
Research that matters to patients

CHULIA
PHARMA SDN BHD

CRM
CLINICAL RESEARCH MALAYSIA
Your Global Solutions in One Nation


SOLBIOTM

Pilot Scale GMP Facility



MVP
MALAYSIAN
VACCINES AND
PHARMACEUTICALS
(Co. No. 82381-X)

pharmaniaga[®]



The background features a light gray molecular structure pattern on the left and a series of colorful dots (red and green) connected by lines on the right. The text "THANK YOU" is centered in the middle.

THANK YOU